Abstract

The disclosed method for classifying microorganisms contained in a sample comprises: preparing a slide of the sample; acquiring at least one digital image of the slide; and implementing, with a computer, a model for predicting the class of the microorganisms depending on the acquired image. According to the invention, said image is subdivided into sub-images and each sub-image is sub-divided into patches, and: A. for each patch, a microorganism feature extractor is applied, the feature extractor forming a convolutional part of a first convolutional neural network trained on patches annotated individually with at least one class; B. for each sub-image, a second neural network connected to the extractor is applied, the second neural network comprising an upstream pooling layer and one or more downstream layers comprising a layer for predicting at least one class, and being trained on training sub-images globally; and C. for the acquired image: F.a. calculating a feature vector calculated for the sub-images; F.b. applying a model for predicting at least one class for the microorganisms.

IPC Classes  ?

• G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
• G06V 10/50 - Extraction of image or video features by performing operations within image blocksExtraction of image or video features by using histograms, e.g. histogram of oriented gradients [HoG]Extraction of image or video features by summing image-intensity valuesProjection analysis
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions

Abstract

A method for in vitro or ex vivo assessment of the risk of complications in a patient admitted to a healthcare facility includes measuring the viral load of at least one torque teno virus (TTV) in a biological sample of the patient, wherein the patient is not undergoing immunosuppressive treatment.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The invention relates to a method for characterising microorganisms which comprises: A. for each wavelength of a predetermined set of wavelengths comprising at least one wavelength, acquiring a holographic digital image, generating a focused image by computer means, each pixel of which image comprises an amplitude value and a phase value, and segmenting the focused image so as to extract portions corresponding to microorganisms; and B. characterising the microorganisms by computer means, according to the focused image portions. According to the invention, prior to the characterisation or prior to the segmentation or prior to the generation of the focused image, the method comprises correcting optical aberrations of the acquisition device by computer means, and the characterisation of the microorganisms comprises applying a digital model to these portions having as descriptors the amplitude and/or phase values of each wavelength of the predetermined set of wavelengths.

IPC Classes  ?

• G03H 1/00 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto
• G03H 1/04 - Processes or apparatus for producing holograms
• G03H 1/26 - Processes or apparatus specially adapted to produce multiple holograms or to obtain images from them, e.g. multicolour technique
• G01N 15/1433 - Signal processing using image recognition
• G01N 15/1434 - Optical arrangements
• G01N 15/10 - Investigating individual particles
• G03H 1/08 - Synthesising holograms
• G06T 7/00 - Image analysis
• G06V 10/143 - Sensing or illuminating at different wavelengths
• G06V 10/22 - Image preprocessing by selection of a specific region containing or referencing a patternLocating or processing of specific regions to guide the detection or recognition
• G06V 10/24 - Aligning, centring, orientation detection or correction of the image
• G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
• G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

An in vitro or ex vivo method for determining the risk of incidence of a healthcare-associated infection in a patient, including a step of measuring the expression of at least one gene encoding a pro-inflammatory cytokine receptor located on chromosome 2 in the region 2q11-2q12, in a biological sample from the patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6851 - Quantitative amplification

Abstract

A method for classifying at least one input image representing a target particle in a sample, involves implementing, by data processing of a client, steps of: (b) extracting the characteristic map of the target particle by a convolutional neural network pre-trained on a base of public images; (c) classifying the input image according to the extracted characteristic map.

IPC Classes  ?

• G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
• G06T 7/10 - SegmentationEdge detection
• G06V 10/24 - Aligning, centring, orientation detection or correction of the image
• G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting

Abstract

The invention relates to a method for characterising microorganisms present in a biological sample, the method comprising acquiring a live holographic digital image of the sample, generating a focused image by using a digital model for reconstructing the focused image and characterising the bacteria on the basis of the focused image. According to the invention, prior to the holographic image being acquired, a plurality of calibration objects are provided in the acquisition field of view, which objects have a previously characterised dimension and refractive index and a shape chosen so that the interference patterns of the objects can be calculated using an image forming model for incorporating optical aberrations of the acquisition device. Prior to the focused image being computer generated, the optical aberrations are qualified according to the interference patterns of the objects and the calculated interference patterns and the digital model for reconstructing the focused image incorporates the quantified optical aberrations.

IPC Classes  ?

• G03H 1/00 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto
• G03H 1/04 - Processes or apparatus for producing holograms
• G03H 1/08 - Synthesising holograms
• G01N 15/02 - Investigating particle size or size distribution
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 15/10 - Investigating individual particles
• G06T 7/00 - Image analysis
• G06V 10/24 - Aligning, centring, orientation detection or correction of the image
• G06T 5/00 - Image enhancement or restoration
• G02B 21/00 - Microscopes

Abstract

A digital holographic imaging technique, includes iterative steps of: a) through back-propagation to the object coordinate of a hologram field comprising a spatial distribution of amplitude corresponding to the spatial distribution of intensity of the hologram and a spatial distribution of phase, determining an object field involving a spatial distribution of absorption and of phase shift of the imaged object, b) thresholding the values of the spatial distribution of absorption and of phase shift by decreasing the values to below a respective threshold, the thresholds decreasing in each iteration, c) through repropagation of the object field to the hologram coordinate, determining a modified hologram field comprising a modified spatial distribution of amplitude and a modified spatial distribution of phase, d) replacing the spatial distribution of phase of the hologram field with the modified spatial distribution of phase, the spatial distribution of phase shift and of absorption of the imaged object being those of the object field of the last iteration.

IPC Classes  ?

• G03H 1/08 - Synthesising holograms
• G03H 1/00 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto
• G03H 1/04 - Processes or apparatus for producing holograms

Abstract

A method for classifying at least one input image containing a target particle in a sample, involves implementing, via data-processing of a client, steps of: (b) extracting a vector of characteristics of the target particle, the characteristics being numerical coefficients each associated with one elementary image of a set of elementary images each representing a reference particle, such that a linear combination of the elementary images weighted by the coefficients approximates the representation of the target particle in the input image; (c) classifying the input image depending on the extracted vector of characteristics.

IPC Classes  ?

• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting

Abstract

A method for classifying at least one input image representing a target particle in a sample involves implementing, by data processing a client, steps of: (B) extracting a characteristic map of the target particle from the input image; (c) reducing the number of variables in the extracted characteristic map, using the t-SNE algorithm; (d) classifying, unsupervised, the input image based on the characteristic map having a reduced number of variables.

IPC Classes  ?

• G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
• G06T 7/11 - Region-based segmentation
• G06V 10/24 - Aligning, centring, orientation detection or correction of the image
• G06V 10/771 - Feature selection, e.g. selecting representative features from a multi-dimensional feature space
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

Abstract

A method for classifying a sequence of input images representing a target particle in a sample over time, includes the following steps performed by the data processing of a client, namely: (b) concatenation of the input images in the sequence as a three-dimensional stack; (c) direct classification of the three-dimensional stack using a convolutional neural network, CNN.

IPC Classes  ?

• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks

Abstract

An in vitro or ex vivo method for determining the risk of complication in a patient, including a step of measuring the expression of C3AR1 in a biological sample from the patient.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Goods & Services

Chemicals for use in industry and science; Chemical additives for food; Chemicals for use in agriculture. Veterinary preparations; Pharmaceuticals; Sanitary preparations for medical purposes; Dietetic foods adapted for medical purposes; Dietetic food adapted for veterinary use; Dietary supplements for human beings and animals; Plasters, materials for dressings. Scientific apparatus and instruments; Weighing apparatus and instruments; Measuring apparatus; Checking (supervision) apparatus and instruments; Data processing equipment; Software; Nautical apparatus and instruments; Surveying apparatus and instruments; Photographic apparatus and instruments; Cinematographic cameras; Optical apparatus and instruments; Measuring apparatus and instruments; Sound recording apparatus; Apparatus for transmission of communication; Apparatus for the transmission of images; Sound reproduction apparatus; Sound transmitting apparatus; Sound and picture recording apparatus; Apparatus for the reproduction of images. Artificial teeth; Surgical apparatus and instruments; Medical apparatus and instruments; Dental equipment; Artificial limbs; Artificial eyes. Teaching; Training; Entertainment services. Scientific technological services; Research and development services; Design services; Industrial analysis and research services; Software design and development. Medical services; Animal healthcare services; Blood bank services; Human tissue bank services.

Abstract

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of CIITA in a biological sample from said patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

An in vitro or ex vivo method for determining the risk of incidence of a care-related infection includes a step of measuring the expression of CD177 in a biological sample from said patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

An in vitro or ex vivo method for determining the risk of incidence of a healthcare-associated infection includes a step of measuring the expression of TAP2 in a biological sample from said patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6813 - Hybridisation assays
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

An in vitro or ex vivo method, based on the measurement of the expression of cytokine(s), from a patient's blood sample, incubated with a stimulus, for determining the risk of occurrence of a healthcare-associated infection in the patient, within seven days following the day on which the collection of the biological sample has been performed from the patient.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a method for in vitro or ex vivo assessment of the risk of complications in a patient admitted to a healthcare facility, the method comprising measuring the viral load of at least one torque teno virus (TTV) in a biological sample of said patient, characterised in that said patient is not undergoing immunosuppressive treatment.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

An in vitro or ex vivo method for determining the risk of occurrence of a healthcare-associated infection in a patient, including a step of measuring the expression of CX3CR1, in a biological sample of said patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

The invention relates to a method for classifying a sequence of input images representing a target particle (11a-11f) in a sample (12) over time, the method being characterized in that it comprises the following steps performed by the data processing means (20) of a client (2), namely: (b) concatenation of the input images in the sequence as a three-dimensional stack; (c) direct classification of the three-dimensional stack using a convolutional neural network, CNN

IPC Classes  ?

• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
• G06K 9/62 - Methods or arrangements for recognition using electronic means

Abstract

The invention relates to a method for classifying at least one input image containing a target particle (11a-11f) in a sample (12), the method being characterized in that it involves implementing, via data-processing means (20) of a client (2), steps of: (b) extracting a vector of characteristics of said target particle (11a-11f), said characteristics being numerical coefficients each associated with one elementary image of a set of elementary images each representing a reference particle, such that a linear combination of said elementary images weighted by said coefficients approximates the representation of said target particle (11a-11f) in the input image; (c) classifying said input image depending on said extracted vector of characteristics.

IPC Classes  ?

• G06V 30/19 - Recognition using electronic means
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

Abstract

The invention relates to a method for classifying at least one input image representing a target particle (11a-11f) in a sample (12), the method being characterized in that it involves implementing, by data processing means (20) of a client (2), steps of: (b) extracting the characteristic map of the target particle (11a-11f) by means of a convolutional neural network pre-trained on a base of public images; (c) classifying the input image according to said extracted characteristic map.

IPC Classes  ?

• G06V 10/22 - Image preprocessing by selection of a specific region containing or referencing a patternLocating or processing of specific regions to guide the detection or recognition
• G06V 10/60 - Extraction of image or video features relating to illumination properties, e.g. using a reflectance or lighting model
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G06V 10/762 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using clustering, e.g. of similar faces in social networks

Abstract

A digital holographic imaging technique, with iterative steps of: a) through back-propagation to the object coordinate of a hologram field comprising a spatial distribution of amplitude corresponding to the spatial distribution of intensity of the hologram and a spatial distribution of phase, determining (S03a) an object field involving a spatial distribution of absorption and of phase shift of the imaged object, b) thresholding (S03b) the values of the spatial distribution of absorption and of phase shift by decreasing the values to below a respective threshold, the thresholds decreasing in each iteration, c) through repropagation of the object field to the hologram coordinate, determining (S03c) a modified hologram field comprising a modified spatial distribution of amplitude and a modified spatial distribution of phase, d) replacing (S03d) the spatial distribution of phase of the hologram field with the modified spatial distribution of phase, the spatial distribution of phase shift and of absorption of the imaged object being those of the object field of the last iteration.

IPC Classes  ?

• G03H 1/00 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto
• G03H 1/04 - Processes or apparatus for producing holograms
• G03H 1/08 - Synthesising holograms

Abstract

The invention relates to a method for classifying at least one input image representing a target particle (11a-11f) in a sample (12), the method being characterized in that it involves implementing, by data processing means (20) of a client (2), steps of: (B) extracting a characteristic map of the target particle (11a-11f) from the input image; (c) reducing the number of variables in the extracted characteristic map, using the t-SNE algorithm; (d) classifying, unsupervised, the input image based on the characteristic map having a reduced number of variables.

IPC Classes  ?

• G06K 9/62 - Methods or arrangements for recognition using electronic means
• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints

Abstract

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of CD177 in a biological sample from said patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of CIITA in a biological sample from said patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of TAP2 in a biological sample from said patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of C3AR1 in a biological sample from said patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to an in vitro or ex vivo method for determining the risk of a care-related infection in a patient, comprising a step of measuring the expression of at least one gene encoding a pro-inflammatory cytokine receptor, located in the region 2q11-2q12 of chromosome 2 in a biological sample of said patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

A support for a multiplex binding experiment is functionalized with at least two different polypeptides. The polypeptides are provided in a reaction mixture along with their cognate binding partners. The polypeptides have high affinity for their cognate binding partners provided in the reaction mixture. The polypeptides and their cognate binding partners can be used in immunoassays.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention provides for a microfluidic droplet-based assay process and apparatus, wherein the process comprises the step of creating several assay droplets (18) containing paramagnetic particles (22, 22′), detectable markers (24), and at least one biological cell (10), wherein the paramagnetic particles (22, 22′) and the detectable markers (24) are able to bind with a target analyte (16) released by the cell, wherein the process includes storing several assay droplets along a horizontal storage plane, includes the generation of a magnetic field through the stored assay droplets, and includes detecting a physical characteristic of the detectable markers contained in a given assay droplet by optical imaging of the detectable markers, characterized in that the generation of a magnetic field generates a magnetic field such that the paramagnetic particles are attracted towards a lateral and inferior portion of the given stored assay droplet in which they are contained.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 21/64 - FluorescencePhosphorescence

Abstract

The present invention relates to an in vitro or ex vivo method based on the measurement of the expression of cytokine(s) from a blood sample of a patient, incubated with a stimulus, for determining the risk of incidence of a care-associated infection in the patient within a period of seven days from the day the blood sample was taken from the patient.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to an in vitro or ex vivo method based on the measurement of the expression of cytokine(s) from a blood sample of a patient, incubated with a stimulus, for determining the risk of incidence of a care-associated infection in the patient within a period of seven days from the day the blood sample was taken from the patient.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a method for detecting the proportion of Gram-positive and Gram-negative bacteria in a complex sample. The bacteria are detected according to the Gram signal thereof. The invention enables distinction between species of Gram-positive bacteria and species of Gram-negative bacteria in a complex sample. The invention also relates to a kit for marking Gram-positive and Gram-negative bacteria, particularly for use in flow cytometry, particularly for complex samples such as human or animal microbiota samples.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-associated infection in a patient, involving a step of measuring the expression of CX3CR1 in a biological sample from said patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

in vitroex vivoex vivo method for determining the risk of incidence of a care-associated infection in a patient, involving a step of measuring the expression of CX3CR1 in a biological sample from said patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.

IPC Classes  ?

• C12N 9/84 - Penicillin amidase
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• C12N 9/86 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention concerns a support for a multiplex binding experiment functionalized with at least two different polypeptides having high affinity to their cognate binding partners provided in a reaction mixture, and their use in e.g. immunoassays.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention concerns a support for a multiplex binding experiment functionalized with at least two different polypeptides having high affinity to their cognate binding partners provided in a reaction mixture, and their use in e.g. immunoassays.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention provides for a microfluidic droplet-based assay process and apparatus, wherein the process comprises the step of creating several assay droplets (18) containing paramagnetic particles (22, 22'), detectable markers (24), and at least one biological cell (10), wherein the paramagnetic particles (22, 22') and the detectable markers (24) are able to bind with a target analyte (16) released by the cell, wherein the process includes storing several assay droplets along a horizontal storage plane, includes the generation of a magnetic field through the stored assay droplets, and includes detecting a physical characteristic of the detectable markers contained in a given assay droplet by optical imaging of the detectable markers, characterized in that the generation of a magnetic field generates a magnetic field such that the paramagnetic particles are attracted towards a lateral and inferior portion of the given stored assay droplet in which they are contained.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to a method for determining in vitro or ex vivo the immune status of an individual, preferably a patient, comprising a step of detecting and/or quantifying the expression of one or more HERV/MaLR sequences in a biological sample of said individual. The invention also relates to the tools for implementing said method and to the uses thereof.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to a method for detecting the proportion of Gram-positive and Gram-negative bacteria in a complex sample. The bacteria are detected according to the Gram signal thereof. The invention enables distinction between species of Gram-positive bacteria and species of Gram-negative bacteria in a complex sample. The invention also relates to a kit for marking Gram-positive and Gram-negative bacteria, particularly for use in flow cytometry, particularly for complex samples such as human or animal microbiota samples.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.

IPC Classes  ?

• C12N 9/86 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

A device for acquisition of particles present in a sample includes a spatially coherent light source, an optical system, and an image sensor placed in the focal plane of the optical system. The image sensor is configured to capture an intensity image. A computational unit of the device is configured to construct a series of electromagnetic propagation matrices obtained for a plurality of defocusing offsets relative to a plane of focus of the optics. The computational unit is also configured to determine a first average focused electromagnetic matrix for the particles from the series of electromagnetic matrices, identifying at least one of the particles in the first electromagnetic matrix and storing the coordinates of said particle, and determining a second electromagnetic matrix at a distance of focus on a particle identified from the components of the series of electromagnetic matrices having the stored coordinates.

IPC Classes  ?

• G03H 1/08 - Synthesising holograms
• G03H 1/04 - Processes or apparatus for producing holograms
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G06T 7/55 - Depth or shape recovery from multiple images
• C12Q 1/20 - Testing for antimicrobial activity of a material using multifield media
• G01N 15/10 - Investigating individual particles
• G01N 21/45 - RefractivityPhase-affecting properties, e.g. optical path length using interferometric methodsRefractivityPhase-affecting properties, e.g. optical path length using Schlieren methods
• G06T 7/00 - Image analysis

Goods & Services

Dental preparations and articles, and medicated dentifrices; Diagnostic preparations and materials; Pharmaceuticals and natural remedies; Cellular function activating agents for medical purposes; Drug delivery agents that facilitate the delivery of pharmaceutical preparations; Yeast extracts for medical, veterinary or pharmaceutical purposes; Blood protein fractions; Microbicides; Blood plasma; Bacteriological preparations for medical purposes; Bacteriological preparations for veterinary purposes; Bacterial preparations for veterinary purposes; Bacterial preparations for medical and veterinary use; Bacterial preparations for medical purposes; Enzyme preparations for medical purposes; Enzyme preparations for veterinary purposes; Veterinary preparations and substances; Medical preparations; Mineral preparations for medical purposes; Preparations for use in naturopathy; Medicinal healthcare preparations; Pharmaceutical preparations for animals; Pharmaceutical preparations for veterinary use; Oral vaccine preparations; Diagnostic radiopharmaceutical preparations; Veterinary preparations; Reagents for use in medical genetic testing; Reagents for use in veterinary genetic testing; Reagents for medical use; Nucleic acid sequences for medical and veterinary purposes; Vaccines; Vaccines for human use; none of the aforementioned goods in respect of ophthalmology or eye care. Scientific and laboratory devices for treatment using electricity; Measuring, detecting and monitoring instruments, indicators and controllers; none of the aforementioned goods in respect of ophthalmology or eye care. Education, entertainment and sport services; Education, entertainment and sports. IT services; Scientific technological services; Design of instruments; Design of diagnostic apparatus and equipment; Constructing an internet platform for electronic commerce; New product design; Design of pipelines; Product design; Design of industrial products; Computer website design; Computer specification design; Design of measurement systems; Computer system design; Design services for data processing systems; Engineering design and consultancy; Design and development of diagnostic apparatus; Design and development of medical diagnostic apparatus; Database design and development; Design and development of testing and analysis methods; Design and development of new products; Design and development of new technology for others; Product design and development; Design and testing for new product development; Design and testing of new products; Scientific and technological design; Product development consultation; Creating and designing website-based indexes of information for others [information technology services]; Development of diagnostic apparatus; Product development; Product development for others; Providing information in the field of product design; Providing information in the field of product development; Research relating to design; Product research and development; Design feasibility studies; Design services relating to data processing test tools; Design services relating to plant for the biotechnology industry; Design services relating to the creation of elementary cells; Design services relating to data processing tools; Design services relating to the publication of documents; Design services relating to data processors; Computer design services; Scientific design services; Technical design services relating to sanitary apparatus and installations; Design services relating to computer hardware and to computer programmes; Engineering consultancy relating to design; Technological services relating to design; Scientific services and design relating thereto; Technological services and design relating thereto; Design services relating to process systems for the biotechnology industry; none of the aforementioned services in respect of ophthalmology or eye care. Animal healthcare services; Human healthcare services; none of the aforementioned services in respect of ophthalmology or eye care.

Abstract

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a Verona integron-encoded metallo-β-lactamase (VIM-2) variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.

IPC Classes  ?

• C12N 9/86 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability.

IPC Classes  ?

• C12N 9/86 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
• A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase

Abstract

The invention relates to the field of probiotics and provides a Lactobacillus paracasei strain capable of improving the immune response to a viral-bacterial coinfection.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 31/04 - Antibacterial agents
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The invention relates to a device (10) for acquiring particles (11a-11f) present in a sample (12), said acquiring device including a spatially coherent light source (15), a lens, an image sensor (16) that is placed in the focal plane of the lens and configured to capture an intensity image and a computational unit that is configured: to construct a series of propagation electromagnetic matrices obtained for a plurality of defocalization offsets with respect to a focal plane of the lens; to determine, for the particles, a first average defocalized electromagnetic matrix on the basis of the series of electromagnetic matrices; to identify at least one of the particles in the first electromagnetic matrix and to store in memory the coordinates of said particle; and to determine, for a particle identified on the basis of components of the series of electromagnetic matrices having the coordinates stored in memory, a second electromagnetic matrix at a focal distance.

IPC Classes  ?

• G01N 21/45 - RefractivityPhase-affecting properties, e.g. optical path length using interferometric methodsRefractivityPhase-affecting properties, e.g. optical path length using Schlieren methods
• G03H 1/00 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto
• G03H 1/08 - Synthesising holograms

Abstract

The invention relates to a nanoparticle which comprises an assembly of encapsulin monomers and in which a peptide has been inserted into the amino acid sequence of at least one of said encapsulin monomers, the insertion site being located outside domain A of the encapsulin monomer, the nanoparticle further comprising an internal protein.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/02 - Bacterial antigens
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability.

IPC Classes  ?

• C12N 9/86 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase

Abstract

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.

IPC Classes  ?

• C12N 9/86 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase

Goods & Services

Dietary supplements and dietetic preparations; Sanitary preparations and articles; Dental preparations and articles, and medicated dentifrices; Pest control preparations and articles; Hygienic preparations and articles; Dental preparations and articles; Live organs and tissues for surgical purpose; Medical dressings, coverings and applicators; Diagnostic preparations and materials; Pharmaceuticals and natural remedies; Marine antifoulants; Cellular function activating agents for medical purposes; Chlorine detoxification agents for medical purposes; Arsenic detoxification agents for medical purposes; Benzol detoxification agents for medical purposes; Drug delivery agents that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; Alcohol for pharmaceutical purposes; Pain relief medication for veterinary purposes; Antibiotics for fish; Animal dips [preparations]; Cachets for medicinal purposes; Cachets for pharmaceutical purposes; Capsules for medicines; Capsules sold empty for pharmaceuticals; Reconstituted cells for clinical treatments for skin care; Reconstituted cells for medical treatments for skin care; Stem cells for medical purposes; Stem cells for veterinary purposes; Living cells for veterinary use; Tobacco-free cigarettes for medical purposes; Bone cement for surgical and orthopaedic purposes; Bone cement for medical purposes; Cement for animal hooves; Surgical cements; Bone cements for surgical purposes; Bone cements for orthopaedic purposes; Collagen for medical purposes; Surgical glues; Collodion for pharmaceutical purposes; Antibiotic food supplements for animals; Nutritional supplements for veterinary use; Feed supplements for veterinary use; Blood components; Chemical contraceptives; Crystals for therapeutic purposes; Bone growth media consisting of biological materials for medical purposes; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Dextrins for pharmaceutical use; Enzymes for medical purposes; Enzymes for veterinary purposes; Cellulose esters for pharmaceutical purposes; Bark extract for medical use; Bark extract for veterinary use; Yeast extracts for medical, veterinary or pharmaceutical purposes; Contraceptive sponges; Chemical contraceptive sponges; Cellulose ethers for pharmaceutical purposes; Blood protein fractions; Petroleum jelly for medical or veterinary purposes; Scrubs [preparations] for medical use; Breath-freshening chewing gum for medicinal purposes; Greases for medical purposes; Greases for veterinary purposes; Vascular grafts [living tissue]; Gelatine for medical purposes; Radiotherapeutic hormones; Sandalwood oil for medical, pharmaceutical and veterinary purposes; Castor oil as a coating for pharmaceuticals; Medicated baby oils; Haemoglobin; Biological indicators for monitoring sterilization processes for medical or veterinary purposes; Isotopes for medical purposes; Yeast for medical, veterinary or pharmaceutical purposes; Impregnated medicated wipes; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Medicated after-shave lotions; Lotions for veterinary purposes; Radio-isotope markers for therapeutic or diagnostic use; Microbicides; Contraceptive foams; Cardiovascular agents for medical purposes; Paracetamol preparations for intravenous administration; Paracetamol preparations for oral administration; Paracetamol modified release preparations; Medicines for veterinary purposes; Pheromones; Blood plasma; Bacterial poisons; Herbal anti-itch ointments for pets; Herbal sore skin ointments for pets; Bark powder for medical use; Pearl powder for medical purposes; Bark powder for veterinary use; Bacterial preparations for medical purposes; Bacterial preparations for medical and veterinary use; Bacterial preparations for veterinary purposes; Bacteriological preparations for medical purposes; Bacteriological preparations for veterinary purposes; Biochemical preparations for medical use; Biochemical preparations for veterinary use; Mixed biological preparations for medical purposes; Biological preparations for medical purposes; Biological preparations for veterinary purposes; Chemical preparations for medical purposes; Chemical preparations for veterinary purposes; Amino acid preparations for medical purposes; Amino acid preparations for veterinary use; Preparations of trace elements for human and animal use; Douching preparations for medical purposes; Medicated toiletry preparations; Trichomycin preparations; Cantharides preparations for medical use; Cantharides preparations for veterinary use; Trace element preparations for human use; Methionine preparations; Mineral food preparations for medical purposes; Antipyretic preparations; Corn remedies; Organotherapeutics; Injectable dermal filler; Trace element preparations for use by animals; Panthenol preparations for medical use; Enzyme preparations for medical purposes; Enzyme preparations for veterinary purposes; Veterinary preparations and substances; Mineral preparations for medical purposes; Medical preparations; Preparations for use in naturopathy; Medicated eye-washes; Medicinal healthcare preparations; Pharmaceutical preparations for animals; Pharmaceutical preparations for treating the symptoms of radiation sickness; Tryptophane preparations; Pharmaceutical preparations for veterinary use; Rehydration preparations; Enema preparations; Bath preparations for medical purposes; Oral vaccine preparations; Diagnostic radiopharmaceutical preparations; Therapeutic preparations for the bath; Medicinal clay preparations; Breath refreshers for medical purposes; Radioactive substances for medical purposes; Veterinary preparations; Reagents for use in medical genetic testing; Reagents for use in veterinary genetic testing; Reagents for medical use; By-products of the processing of cereals for medical purposes; Cord blood for medical purposes; Cord blood; Blood for medical purposes; Leeches for medical purposes; Bath salts for medical purposes; Pre-filled syringes for medical purposes; Medicated shampoos; Medicated shampoos for pets; Medicated dry shampoos; Nucleic acid sequences for medical and veterinary purposes; Cooling sprays for medical purposes; Feeding stimulants for animals; Blood substitutes; Milk sugar for medical purposes [lactose]; Chromatographic supports for medical use; Trypsins for medical purposes; Urease for medical purposes; Vaccines; Vaccines for human use. Scientific research and laboratory apparatus, educational apparatus and simulators; Recorded content; Information technology and audio-visual, multimedia and photographic devices; Scientific and laboratory devices for treatment using electricity; Measuring, detecting and monitoring instruments, indicators and controllers; Information technology and audiovisual equipment. Publishing and reporting; Education, entertainment and sport services; Organisation of conferences, exhibitions and competitions; Audio, video and multimedia production, and photography; Education and instruction services; Hosting [organising] awards; Education, entertainment and sports. Design services; Scientific technological services; Testing, authentication and quality control; IT services. Animal healthcare services; Human healthcare services; Human hygiene and beauty care; Agriculture, aquaculture, horticulture and forestry services.